Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | GPR3 | P46089 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.46 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.46 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.46 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.46 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.46 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.46 |
| ▸ | GABRP | O00591 | 3/20 | 0.46 |
| ▸ | GABRD | O14764 | 3/20 | 0.46 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.46 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.46 |
| ▸ | GABRE | P78334 | 3/20 | 0.46 |
| ▸ | GABRA6 | Q16445 | 3/20 | 0.46 |
| ▸ | GABRG1 | Q8N1C3 | 3/20 | 0.46 |
| ▸ | GABRG3 | Q99928 | 3/20 | 0.46 |
| ▸ | GABRQ | Q9UN88 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29506294 | 1.00 | ALDH1A1 (0.48) | ALDH1A1GPR3HSD17B10GABRA1GABRG2 | |
| SCHEMBL2461988 | 0.78 | CDK4 (0.53) | ALDH1A1GPR3HSD17B10GABRA1GABRG2 | |
| SCHEMBL31609494 | 0.74 | ALDH1A1 (0.50) | ALDH1A1GPR3HSD17B10GABRA1GABRG2 | |
| SCHEMBL4934675 | 0.74 | ALDH1A1 (0.50) | ALDH1A1GPR3HSD17B10GABRA1GABRG2 | |
| SCHEMBL31485824 | 0.73 | ALDH1A1 (0.48) | ALDH1A1GPR3HSD17B10GABRA1GABRG2 | |
| SCHEMBL1521622 | 0.72 | MAPT (0.58) | ALDH1A1GPR3HSD17B10GABRA1GABRG2 | |
| SCHEMBL602244 | 0.71 | ALDH1A1 (0.64) | ALDH1A1GPR3HSD17B10GABRA1GABRG2 | |
| SCHEMBL2391060 | 0.69 | GABRA1 (0.53) | ALDH1A1GPR3HSD17B10GABRA1GABRG2 | |
| Carbazole SCHEMBL16505004 | 0.69 | ALDH1A1 (0.67) | ALDH1A1GPR3HSD17B10GABRA1GABRG2 | |
| SCHEMBL4147114 | 0.69 | MAPT (0.36) | ALDH1A1GPR3HSD17B10SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004096808-A1 | TRIAZINE COMPOUNDS AND THEIR USE | DE NOVO PHARMACEUTICALS LIMITED (GB) | 2004-11-11 | — | — | WO | claimed |
| EP-3551183-B1 | INHIBITORS OF MECHANOTRANSDUCTION TO TREAT PAIN AND MODULATE TOUCH PERCEPTION | MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN HELMHOLTZ GEMEINSCHAFT (DE) | 2025-08-20 | — | — | EP | disclosed |
| US-9447103-B2 | Inauhzin analogues that induce P53, inhibit cell growth, and have antitumor activity | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) | 2016-09-20 | — | — | US | disclosed |
| US-20150197522-A1 | INAUHZIN ANALOGUES THAT INDUCE P53, INHIBIT CELL GROWTH, AND HAVE ANTITUMOR ACTIVITY | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORP. (US) | 2015-07-16 | — | — | US | disclosed |
| WO-2014018953-A1 | INAUHZIN ANALOGUES THAT INDUCE P53, INHIBIT CELL GROWTH, AND HAVE ANTITUMOR ACTIVITY | INDIANA UNIVERSITY RESARCH AND TECHNOLOGY CORPORATION (US) | 2014-01-30 | — | — | WO | disclosed |
| EP-2536410-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS | Merck Sharp & Dohme Corp. (US) | 2012-12-26 | — | — | EP | disclosed |
| WO-2012135149-A9 | SMALL MOLECULE MODULATORS OF SIRT1 ACTIVITY ACTIVATE P53 AND SUPPRESS TUMOR GROWTH | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2012-11-22 | — | — | WO | disclosed |
| WO-2012135149-A2 | SMALL MOLECULE MODULATORS OF SIRT1 ACTIVITY ACTIVATE P53 AND SUPPRESS TUMOR GROWTH | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2012-10-04 | — | — | WO | disclosed |
| WO-2004096808-A1 | TRIAZINE COMPOUNDS AND THEIR USE | DE NOVO PHARMACEUTICALS LIMITED (GB) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150197522-A1 | INAUHZIN ANALOGUES THAT INDUCE P53, INHIBIT CELL GROWTH, AND HAVE ANTITUMOR ACTIVITY | TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NOP58 | ALDH1A1 2127/4885GPR3 4113/4885HSD17B10 3940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.